Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00320385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens
Study identification
- NCT ID
- NCT00320385
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 296 participants
Conditions and interventions
Conditions
Interventions
- Lapatinib Drug
- Trastuzumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- May 31, 2007
- Completion
- Sep 30, 2010
- Last update posted
- Feb 25, 2016
2005 – 2010
United States locations
- U.S. sites
- 87
- U.S. states
- 25
- U.S. cities
- 82
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Phoenix | Arizona | 85012 | — |
| GSK Investigational Site | Sedona | Arizona | 86336 | — |
| GSK Investigational Site | Highland | California | 92346 | — |
| GSK Investigational Site | Sacramento | California | 95819 | — |
| GSK Investigational Site | San Diego | California | 92120 | — |
| GSK Investigational Site | San Francisco | California | 94115-1710 | — |
| GSK Investigational Site | Santa Rosa | California | 95403-1757 | — |
| GSK Investigational Site | Vallejo | California | 94589 | — |
| GSK Investigational Site | Newark | Delaware | 19713 | — |
| GSK Investigational Site | Boca Raton | Florida | 33428 | — |
| GSK Investigational Site | Fort Myers | Florida | 33916 | — |
| GSK Investigational Site | Gainesville | Florida | 32605 | — |
| GSK Investigational Site | Hollywood | Florida | 33021 | — |
| GSK Investigational Site | Jacksonville | Florida | 32256 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Ocala | Florida | 34474 | — |
| GSK Investigational Site | Ocoee | Florida | 34761 | — |
| GSK Investigational Site | Orlando | Florida | 32804 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33401 | — |
| GSK Investigational Site | Lawrenceville | Georgia | 30046-7650 | — |
| GSK Investigational Site | Niles | Illinois | 60714 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46227 | — |
| GSK Investigational Site | Terre Haute | Indiana | 47802 | — |
| GSK Investigational Site | Cedar Rapids | Iowa | 52403 | — |
| GSK Investigational Site | Kansas City | Kansas | 66103 | — |
| GSK Investigational Site | Overland Park | Kansas | 66210 | — |
| GSK Investigational Site | Boston | Massachusetts | 02115 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55404 | — |
| GSK Investigational Site | Robbinsdale | Minnesota | 55422 | — |
| GSK Investigational Site | Columbia | Missouri | 65201 | — |
| GSK Investigational Site | Saint Joseph | Missouri | 64507 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89109 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89135 | — |
| GSK Investigational Site | Montclair | New Jersey | 07042 | — |
| GSK Investigational Site | Morristown | New Jersey | 07962 | — |
| GSK Investigational Site | New Brunswick | New Jersey | 08901 | — |
| GSK Investigational Site | Summit | New Jersey | 07901 | — |
| GSK Investigational Site | Voorhees Township | New Jersey | 08043 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | Cary | North Carolina | 27511 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28203 | — |
| GSK Investigational Site | Durham | North Carolina | 27710 | — |
| GSK Investigational Site | Hickory | North Carolina | 28602 | — |
| GSK Investigational Site | Canton | Ohio | 44710 | — |
| GSK Investigational Site | Kettering | Ohio | 45409 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74136-1902 | — |
| GSK Investigational Site | Bryn Mawr | Pennsylvania | 19010 | — |
| GSK Investigational Site | Hershey | Pennsylvania | 17033 | — |
| GSK Investigational Site | Kingston | Pennsylvania | 18704 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| GSK Investigational Site | West Reading | Pennsylvania | 19611 | — |
| GSK Investigational Site | Greenville | South Carolina | 29605 | — |
| GSK Investigational Site | Nashville | Tennessee | 37203 | — |
| GSK Investigational Site | Arlington | Texas | 76014 | — |
| GSK Investigational Site | Austin | Texas | 78731 | — |
| GSK Investigational Site | Beaumont | Texas | 77702-1449 | — |
| GSK Investigational Site | Bedford | Texas | 76022 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Dallas | Texas | 75231 | — |
| GSK Investigational Site | Dallas | Texas | 75237 | — |
| GSK Investigational Site | Dallas | Texas | 75246 | — |
| GSK Investigational Site | Denton | Texas | 76210 | — |
| GSK Investigational Site | El Paso | Texas | 79915 | — |
| GSK Investigational Site | Fort Worth | Texas | 76104 | — |
| GSK Investigational Site | Fredericksburg | Texas | 78624 | — |
| GSK Investigational Site | Lewisville | Texas | 75067 | — |
| GSK Investigational Site | Longview | Texas | 75601 | — |
| GSK Investigational Site | McAllen | Texas | 78503-1298 | — |
| GSK Investigational Site | Mesquite | Texas | 75150 | — |
| GSK Investigational Site | Midland | Texas | 79701 | — |
| GSK Investigational Site | Odessa | Texas | 79761 | — |
| GSK Investigational Site | Paris | Texas | 75460 | — |
| GSK Investigational Site | Tyler | Texas | 75702 | — |
| GSK Investigational Site | Waco | Texas | 76712 | — |
| GSK Investigational Site | Norfolk | Virginia | 23502 | — |
| GSK Investigational Site | Richmond | Virginia | 23230 | — |
| GSK Investigational Site | Salem | Virginia | 24153 | — |
| GSK Investigational Site | Edmonds | Washington | 98026 | — |
| GSK Investigational Site | Seattle | Washington | 98133 | — |
| GSK Investigational Site | Spokane | Washington | 99202 | — |
| GSK Investigational Site | Vancouver | Washington | 98684 | — |
| GSK Investigational Site | Yakima | Washington | 98902 | — |
| GSK Investigational Site | Green Bay | Wisconsin | 54301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00320385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2016 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00320385 live on ClinicalTrials.gov.